Windy with rain and snow showers this evening transitioning to snow showers overnight. Low 32F. Winds WSW at 20 to 30 mph. Chance of precip 50%. Winds could occasionally gust over 40 mph..
Windy with rain and snow showers this evening transitioning to snow showers overnight. Low 32F. Winds WSW at 20 to 30 mph. Chance of precip 50%. Winds could occasionally gust over 40 mph.
Updated: January 19, 2023 @ 6:10 pm
Novartis Ag ADR (NY: NVS )
92.00 +0.42 (+0.46%) Official Closing Price Updated: 6:30 PM EDT, Mar 31, 2023 Add to My Watchlist
Headline News about Novartis Ag ADR
US Stocks On Track For Nervous Start As Traders Go Fed Watching: AMD Earnings Calm Investors
February 01, 2023
Futures trading point to a negative start by Wall Street stocks on Wednesday as traders exercise restraint ahead of the Fed decision due in the afternoon. Cues From Tuesday’s Trading:
Hopeful Golden Cross Forms On Novartis's Chart
December 26, 2022
5 Value Stocks In The Healthcare Sector
December 26, 2022
A Bullish Sign Appears On Novartis's Chart
December 23, 2022
A Preview Of Novartis's Earnings
January 31, 2023
Philips Reports Q4 Earnings, To Lay Off Additional Employees This Year, Shares Jump
January 30, 2023
Koninklijke Philips NV (NYSE: PHG) would reduce its workforce by an additional 6,000 roles globally by 2025, of which 3,000 will be implemented in 2023 to restore its profitability following a recall...
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
January 29, 2023
With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed.
Novartis CEO Refutes Recent Report Of Weighing Options For Ophthalmology, Respiratory Units
January 10, 2023
Novartis AG (NYSE: NVS) said it would narrow its focus on five core therapeutic areas, including cardiovascular, immunology, neurodegenerative diseases, solid tumors, and hematology.
GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca
December 30, 2022
GSK plc (NYSE: GSK) chief commercial officer Luke Miels says the company is looking at M&A targets that are under-appreciated worth $1 billion-$2.5 billion and avoid getting into a 'bidding war.'
Novartis AG (NYSE: NVS) will pay $245 million to end antitrust litigation accusing the company of trying to delay the U.S. launch of generic versions of its Exforge, which treats hypertension to lower...
The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies. Here’s the latest list of major overbought players in this sector, with an RSI...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following